Adjuvant Chemotherapy or Not for NPC Patients Staged N2-3M0 After Concurrent Chemotherapy :a Phase Ⅱ Study
Recent research (Lancet Oncology 2012)shows that no survival benefits were achieved by
adding adjuvant chemotherapy after concurrent chemoradiation in patients with locoregionally
advanced NPC. But in patients with even high risk of distant metastasis(staged N2-3M0),is
adjuvant chemotherapy necessary?
Interventional
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
treatment toxicity based on a CTCAE3.0 grading system
6 months
Yes
Xia He, M.D. and PhD
Principal Investigator
Department of Radiotherapy,Jiangsu Cancer Hospital
United States: Food and Drug Administration
NPC-N23-RCT
NCT01694576
September 2012
October 2014
Name | Location |
---|